Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOE: Rosiglitazone and Metformin for Diabetes Prevention
NCT00116922Phase 3Completed
- Sponsor
- Mount Sinai Hospital
- Start
- Jun 2004
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Development of diabetes. Started Jun 2004; status: completed.
02
Drugs
rosiglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00116922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116922.